🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Bladder Cancer
Clinical trial register · China

Bladder Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Guangzhou 16 Shanghai 12 Beijing 10 Tianjin 8 Nanjing 8
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University7 Tianjin Medical University Second Hospital6 Qilu Hospital of Shandong University4 RenJi Hospital3 Peking University First Hospital3
Site location
Guangzhou16 Shanghai12 Beijing10 Tianjin8 Nanjing8
All 37 locations
Target enrolment
to

Bladder Cancer trials in China

50 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Study to Evaluate the Efficacy and Safety of Intravesical Instillation of Disitamab Vedotin Combined With Toripalimab in Patients With HER2-Positive High-Risk Non-Muscle Invasive Bladder Cancer Who Are BCG-Naïve or Have BCG Failure
NCT07783815Bladder Cancer
DrugTislelizumab
Xiangya Hospital of Central South University
Phase 1
20
Changsha
2026-09-01
Not yet open
Active Surveillance Versus Adjuvant Intravesical Chemotherapy in Liquid Biopsy-Defined Low-Shedding Intermediate-Risk NMIBC
NCT07749924Bladder Cancer, Non-Muscle-Invasive Bladder Cancer (NMIBC)
Tianjin Medical University Second Hospital
Not applicable
670
Daqing, Nanchang, Tianjin
2026-08-10
Not yet open
Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder Cancer
NCT07756008Bladder Urothelial Carcinoma, Muscle-invasive Bladder Cancer, Bladder Cancer
DrugsDisitamab Vedotin·Tislelizumab
Tianjin Medical University Second Hospital
Phase 2/3
114
Tianjin
2026-08-01
Not yet open
Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)
NCT07662863Bladder Cancer, Metastatic Urothelial Carcinoma, Urothelial Carcinoma, Peripheral Neuropathy
DrugSacituzumab tirumotecan
Fudan University
Phase 2
75
Shanghai
2026-07-15
Recruiting
Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer
NCT07717242Bladder Urothelial Carcinoma, Bladder Cancer
DrugsSitagliptin·Tafolecimab·Ursodeoxycholic Acid·Zeprumetostat
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
80
Guangzhou
2026-07-01
Not yet open
PTC-guided Neoadjuvant Therapy For Muscle-invasive Bladder Cancer
NCT07690878Bladder Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 2
35
Nanjing
2026-07
Recruiting
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)
NCT07419295Bladder Cancer
DrugsVinflunine·Sacituzumab tirumotecan·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
590
Beijing, Chongqing, Guangzhou, Zhuhai, Wuhan, Changsha, Nanjing, Nanchang
2026-04-23
Recruiting
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
NCT07475403Bladder Cancer, Liquid Biopsy, Immunotherapy
Tianjin Medical University Second Hospital
Phase 2
53
Tianjin, Xingtai
2026-03-16
Recruiting
Dual-Target Nectin-4/HER2 CAR-NK Cells in Advanced Urothelial Carcinoma
NCT07492628Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
DrugsFludarabine·Cyclophosphamide
Beijing Biotech
Phase 1
42
Shenzhen
2026-03-02
Recruiting
Detecting CREPT in Urine for Bladder Cancer Diagnosis and Monitoring
NCT07514897Bladder Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
250
Beijing
2026-03-01
Recruiting
Multiplex Mutation Detection Using Mass Spectrometry in Bladder Cancer
NCT07424560Bladder Cancer, Bladder Cancer Recurrence, Adjuvant Therapy for Bladder Cancer, Progression of Bladder Cancer
Zhilong Dong
Observational
400
Lanzhou
2026-02-25
Recruiting
Toripalimab Combined With BCG Perfusion for the Treatment of HR-NMIBC After TURBT Surgery Exploration
NCT07307456Bladder Cancer
Changhai Hospital
Phase 2
31
Shanghai
2025-12-08
Not yet open
Entinostat & Chemotherapy for Locally Advanced or Metastatic Bladder Cancer
NCT07261592Bladder Cancer, Histone Deacetylase Inhibitor, Entinostat, Chemotherapy
DrugEntinostat
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Phase 1/2
29
Nanjing
2025-12-01
Active, closed
Microfluidic Urinary Exosome-Based Diagnostic Model for Bladder Cancer
NCT07735858Bladder Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
300
Beijing
2025-10-01
Not yet open
A Clinical Trail to Determine the Safety and Efficacy of the Combination of Tislelizumab With Cisplatin and Gemcitabine, With or Without Trilaciclib for Patients With Untreated Unresectable and Metastatic Urothelial Carcinoma.
NCT06364904Bladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
210
Guangzhou, Wuhan, Changsha
2025-10
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
NCT07187635Bladder Cancer, Liquid Biopsy, Repeat Transurethral Resection of Bladder Tumor
Tianjin Medical University Second Hospital
Not applicable
196
Nanchang, Guangzhou, Xingtai, Kunming, Shanghai, Tianjin
2025-09-28
Recruiting
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
NCT07129993Urothelial Cancer, Bladder Cancer
DrugsDato-DXd·Gemcitabine·Cisplatin·Carboplatin
Daiichi Sankyo
Phase 2/3
630
Beijing, Chengdu, Guangzhou
2025-09-26
Recruiting
Guiding Value of Urinary Tumor DNA Testing in Cystoscopy for High-Risk/Very High-Risk Non-Muscle-Invasive Bladder Cancer
NCT07180212Bladder Cancer, Liquid Biopsy, Cystoscopy
Tianjin Medical University Second Hospital
Not applicable
360
Xingtai, Guangzhou, Haerbin, Kunming, Nanchang, Tianjin
2025-09-20
Recruiting
Investigation Into the Integration of Intracavitary Cryoablation and Immunotherapy in Bladder-Preserving Therapy
NCT07204132Bladder Cancer
Changhai Hospital
Not applicable
180
Shanghai
2025-09-01
Recruiting
The Guiding Value of Liquid Biopsy Based on Urinary Tumor DNA/RNA in the Second Transurethral Resection of High-risk Non-muscle Invasive Bladder Cancer
NCT07130578Bladder Cancer, Liquid Biopsy
Tianjin Medical University Second Hospital
Observational
60
Tianjin
2025-09-01
Recruiting
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
NCT07090499Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer
Pfizer
Phase 1
540
Changsha
2025-08-20
Recruiting
Construction of a Deep Learning-Based Precise Diagnostic Framework for Bladder Tumors Using Ultrasound: A Multicenter, Ambispective Cohort Study
NCT07111364Deep Learning, Ultrasound, Bladder Cancer
Peking University First Hospital
Observational
400
Beijing
2025-05-27
Not yet open
Disitamab Vedotin Combined With Ivonescimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
NCT06957561Bladder Cancer, Muscle-invasive Bladder Cancer
DrugDisitamab Vedotin
Sun Yat-sen University
Phase 1/2
30
Guangzhou
2025-04-30
Recruiting
Development of an AI-Agent for Urological Disease Diagnosis and Treatment
NCT07721935Urinary Stones, Prostate Cancer, Bladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
2,000
Guangzhou, Shantou, Ganzhou
2025-04-01
Recruiting
Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
NCT06926374Colorectal Carcinoma, Rectal Prolapse, Prostate Cancer (Adenocarcinoma), Bladder Cancer
Chinese University of Hong Kong
Not applicable
90
Hong Kong
2025-03-25
Recruiting
The Efficacy of Gallium[68Ga]NOTA-DNA Multivalent SGC8 Injection for Bladder Tumour Imaging
NCT06763354Bladder Cancer
RenJi Hospital
Not applicable
20
Shanghai
2025-02-08
Recruiting
Evaluating the Efficacy of Neoadjuvant Chemotherapy Drugs Based on Organoid Technology
NCT07379281Bladder Cancer
Qilu Hospital of Shandong University
Observational
254
Jinan
2025-01-01
Recruiting
Evaluation of the Efficacy of Anti-HER2 Antibody-Drug Conjugates (ADC) in Locally Advanced or Metastatic Bladder Cancer Based on Organoid Technology.
NCT07379268Bladder Cancer
Qilu Hospital of Shandong University
Observational
224
Jinan
2025-01-01
Recruiting
Evaluation of Postoperative Adjuvant Chemotherapy Efficacy for Bladder Cancer Based on Organoid Technology.
NCT07379255Bladder Cancer
Qilu Hospital of Shandong University
Observational
266
Jinan
2025-01-01
Recruiting
Trop2-targeted immunoPET Imaging of Solid Tumors
NCT06851663Solid Tumor, Solid Carcinoma, Uroepithelial Carcinoma, Bladder Cancer
Drugs[68Ga]Ga-NOTA-RT4·[18F]F-RESCA-RT4·[18F]F-RESCA-T4·[68Ga]Ga-NOTA-T4
RenJi Hospital
Phase 2/3
400
Shanghai
2024-12-23
Recruiting
A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer
NCT06735287Bladder Cancer, NMIBC
The First Affiliated Hospital with Nanjing Medical University
Not applicable
60
Nanjing
2024-12-01
Recruiting
Adaptive Radiotherapy for Genitourinary Cancers
NCT07324798Prostate Cancer (Post Prostatectomy), Bladder Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Not applicable
60
Beijing
2024-12-01
Recruiting
A Research Protocol for Evaluating the Efficacy of Perfused Chemotherapeutic Agents for Bladder Cancer Based on Organoid Technology
NCT06662071Bladder Cancer
Qilu Hospital of Shandong University
Observational
293
Binzhou, Dezhou, Jinan, Jining, Liaocheng, Linyi, Qingdao, Taian
2024-10-01
Recruiting
Comparison Capsule Sparing Cystectomy and Radical Cystoprostatectomy in Men with Bladder Cancer
NCT05067101Bladder Cancer
Zhujiang Hospital
Not applicable
126
Guangzhou
2024-09-10
Not yet open
Performance Evaluation of Urine DNA Methylation Testing for the Detection of Urothelial Carcinoma in Patients With Hematuria
NCT06469229Hematuria, Urothelial Carcinoma, Bladder Cancer, Ureter Cancer
Changhai Hospital
Observational
1,200
Shanghai
2024-07-01
Recruiting
RC48 Combined with Toripalimab As Neoadjuvant Therapy for Cisplatin Ineligible MIBC Patients
NCT06341400Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Zhujiang Hospital
Phase 1/2
55
Guangzhou
2024-06-19
Recruiting
Clinical Trail of Neoadjuvant of Tislelizumab Combined With Palbociclib in Patients With Platinum-refractory Bladder Urothelial Carcinoma
NCT06364956Bladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 1/2
36
Guangzhou, Wuhan, Changsha
2024-05-15
Recruiting
Ultrasound Contrast-Enhanced Accurate Diagnosis of Preoperative Staging of Bladder Cancer
NCT06775977Bladder Cancer, Staging, Contrast Enhanced Ultrasound
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
480
Guangzhou
2024-01-01
Recruiting
Bladder Cancer Staging and Prediction of New Adjuvant Chemotherapy Efficacy Based on Deep Learning and Transfer Learning in Ultrasound-Magnetic Resonance-Pathology Multimodal Multiscale
NCT07051083Bladder Cancer, Staging, Deep Learning, Neoadjuvant Chemotherapy
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
480
Guangzhou
2024-01-01
Recruiting
Whole-slide Image and CT Radiomics Based Deep Learning System for Prognostication Prediction in Bladder Cancer
NCT06389019Bladder Cancer
Mingzhao Xiao
Observational
1,000
Chongqing
2024-01-01
Recruiting
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma
NCT06091124Neuroendocrine Carcinoma of the Bladder, Bladder Cancer
DrugsCDDP·Etoposide·Adebrelimab·Cisplatin
RenJi Hospital
Phase 2
22
Nanjing, Xi'an, Shanghai, Chengdu, Tianjin
2023-11-16
Recruiting
Deep Learning Radiomics Model for Predicting Post-cystectomy Outcome in Muscle Invasive Bladder Cancer
NCT06092450Bladder Cancer
First Affiliated Hospital of Chongqing Medical University
Observational
500
Chongqing
2023-08-01
Active, closed
A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
NCT05714202Bladder Cancer
DrugsTAR-200·Cetrelimab
Janssen Research & Development, LLC
Phase 3
1,135
Beijing, Changchun, Changsha, Chengdu, Chongqing, Deyang, Guangzhou, Hangzhou
2023-03-23
Active, closed
Risk-stratification Based Bladder-sparing Modalities for Muscle-invasive Bladder Cancer
NCT05531123Bladder Cancer
DrugsGemcitabine and cisplatin·Tislelizumab
Fudan University
Phase 2
30
Shanghai
2022-09-10
Recruiting
Safety, Tolerability, and Preliminary Efficacy of BH011 in Subjects With Non-Muscle-Invasive Bladder Cancer
NCT06732531Bladder Cancer, Non Muscle Invasive
DrugPaclitaxel
Zhuhai Beihai Biotech Co., Ltd
Phase 1/2
48
Beijing, Xiamen, Changsha, Shenyang, Shanghai, Tianjin
2022-08-03
Recruiting
Pembrolizumab Monotherapy Following Tri-modality Treatment for Selected Patients With Muscle-invasive Bladder Cancer
NCT05072600Bladder Cancer, Bladder Neoplasms, Bladder Tumors, Urinary Bladder Cancer
Peking University First Hospital
Phase 2
54
Beijing
2021-12-07
Recruiting
Prognostic Effect of Whether Doing PLND During RC for High-risk NMIBC
NCT05123625Bladder Cancer
The First Affiliated Hospital with Nanjing Medical University
Not applicable
200
Nanjing
2021-07-01
Active, closed
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
NCT04700124Bladder Cancer
DrugsEnfortumab Vedotin·Gemcitabine·Cisplatin·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
808
Guangzhou, Changsha, Nanjing, Nantong, Shanghai
2021-04-21
Recruiting
Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
NCT04532606Benzodiazepines, Bladder Cancer, Delirium, Surgery
DrugsRemimazolam·Propofol
Peking University First Hospital
Phase 4
1,128
Beijing, Beijin, Guiyang, Nanjing, Shanghai
2021-02-05
Recruiting
Preoperative Detection of Muscle Invasion in Bladder Cancer with Contrast-enhanced Ultrasonography
NCT05204108Bladder Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Observational
1,000
Guangzhou
2020-04-01
Rows per page Showing 1–50 of 50
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/bladder-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 50 of those studies listing the condition Bladder Cancer.

How many Bladder Cancer trials are recruiting in China?

37 of the 50 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 9 have not yet opened recruitment, 4 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Bladder Cancer), 50 studies
PhaseStudiesRecruitingShare
Observational161432%
Not applicable10920%
Phase 28516%
Phase 1/25310%
Phase 3418%
Phase 1326%
Phase 2/3326%
Phase 4112%

Most active sponsors

Lead sponsors with the most studies (Bladder Cancer)
Lead sponsorStudiesRecruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University76
Tianjin Medical University Second Hospital64
Qilu Hospital of Shandong University44
Cancer Institute and Hospital, Chinese Academy of Medical Sciences32
Changhai Hospital32
Peking University First Hospital33
RenJi Hospital33
Fudan University20
Merck Sharp & Dohme LLC21
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School20
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.